Skip to main content

Table 3 Percent of Months of Treatment in which Multiple ADHD Medications were Prescribed

From: A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)

Drug Class
(number of months of therapy excluding first months)
LAS IAS SAS ATX BUP A2A Any other ADHD medication
LAS (34,239) 79.0 1.0 9.5 1.9 9.3 1.1 21.0
IAS (11,200) 2.5 72.6 17.1 1.1 8.4 0.8 27.4
SAS (31,239) 9.1 5.9 76.9 1.5 7.8 1.0 23.1
ATX (8,141) 6.7 1.0 4.7 80.3 8.6 1.0 19.7
BUP (18,318) 17.0 5.0 13.5 4.4 63.1 1.2 36.9
A2A (1,639) 22.3 5.5 18.3 5.7 12.2 47.0 53.0
  1. Rows represent therapy of focus. Percents represent breakout of proportion of months in combination with other therapies. Numbers on the diagonal from top left to lower right represent number of months on monotherapy on Long-Acting Stimulants (LAS), Intermediate-Acting Stimulants (IAS), Short-Acting Stimulants (SAS), Atomoxetine (ATX), Bupropion (BUP), and Alpha-2 Adrenergic Agonists (A2A). Row sums across individual drug classes may be larger than the value shown for combination with any class due to more than 2 classes being prescribed in combination.